Bexarotene
Active Pharmaceutical Ingredients 2025-03-03
Catalog ID80071728
CAS NO.153559-49-0
Purity 96%
MDL NumberMFCD00932428
Molecular Formula C24H28O2
Molecular Weight 348.483
Melting point: 220-225°C
| Item | Information |
|---|---|
| Mechanism of Action | Bexarotene is a selective retinoid X receptor (RXR) agonist. It regulates gene expression involved in cell differentiation, proliferation, and apoptosis, thus inhibiting cancer cell growth. |
| Therapeutic Uses | Primarily used to treat cutaneous T-cell lymphoma (CTCL) in patients who have not responded to other treatments. It is also under investigation for other cancers. |
| Formulations | Available as capsules (75 mg) and topical gel. |
| Dosage | The recommended oral dose is 300 mg/m² daily, which can be adjusted based on patient response and tolerance. |
| Side Effects | Common side effects include hyperlipidemia, headache, dry skin, and photosensitivity. Severe adverse events may include hepatotoxicity, pancreatitis, and teratogenic effects. |
| Drug Interactions | Bexarotene is metabolized by CYP3A4; thus, inhibitors of this enzyme (e.g., ketoconazole, clarithromycin) can increase plasma levels of bexarotene and should be avoided. |
| Storage Conditions | Store powder at -20°C for 3 years; in solvent at -80°C for 1 year. |
| Approval and Brand Name | Approved by the FDA in 1999. Marketed under the brand name Targretin. |
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
